Stock Events

Hyloris Pharmaceuticals SA 

€11.8
14
-€0.25-2.07% Friday 16:35

Statistics

Day High
12.15
Day Low
11.8
52W High
14.1
52W Low
10.6
Volume
9,402
Avg. Volume
10,244
Mkt Cap
332.7M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

1SepConfirmed
Q1 2020
Q2 2020
Q1 2021
Q2 2021
Q1 2022
Q2 2022
-0.36
-0.24
-0.12
0
Expected EPS
0
Actual EPS
-0.19

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HYL.BR. It's not an investment recommendation.

About

Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health, oncology, women's health, and other major therapeutic areas. The company offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary heart disease. It also provides other products, such as post operation pain, dental indications, severe and recurring vulvovaginal candidiasis, acute myeloid leukemia and small cell lung cancer, IC/PBS, attention deficit hyperactivity disorder, and viral infection. Hyloris Pharmaceuticals SA was incorporated in 2012 and is headquartered in Liège, Belgium.
Show more...
CEO
Mr. Stijn Van Rompay
Employees
21
Country
BE
ISIN
BE0974363955
WKN
000A2P7Y0

Listings